I don't recall DM getting into the screening protocols for this P2 COVID trial, but I can't help but think: (1) patient is a T2D; (2) history of ACS and / or CKD.  Which covers a wide population.  Get to them early (7 days ) and it makes sense there would be a high chance af success.

What he definitely didn't touch on (and I've posted on several times) are those patients - also with T2D; and heart damage/kidney damage - who have survived, but have a risk of succumbing to the disease due to the long-term health effects on their organs.  I hope someone in the company and the health system picks up on this and starts putting 2 and 2 together.

...so basically a short-term therapeutic, but also a long-term therapeutic

who knows? maybe the Sheikh is just being pro-active about his own health and his investment comes with a lifetime supply of Apabetalone.